Evaluating the Association between Serum Concentrations of Per- and Polyfluoroalkyl Substances (PFAS) and Symptoms and Diagnoses of Selected Acute Viral Illnesses

ICR 202208-0923-001

OMB:

Federal Form Document

Forms and Documents
Document
Name
Status
Form and Instruction
Unchanged
Form and Instruction
Modified
Form and Instruction
Unchanged
Form and Instruction
Modified
Form and Instruction
Unchanged
Form and Instruction
Modified
Form and Instruction
Unchanged
Form and Instruction
Modified
Form and Instruction
Unchanged
Form and Instruction
Modified
Form and Instruction
Unchanged
Form and Instruction
Modified
Supporting Statement B
2022-08-01
Supporting Statement A
2022-08-01
Supplementary Document
2022-08-01
Supplementary Document
2022-08-01
Supplementary Document
2022-01-07
Supplementary Document
2022-01-07
Supplementary Document
2022-01-07
Supplementary Document
2022-08-01
Supplementary Document
2022-08-01
Supplementary Document
2022-01-07
Supplementary Document
2022-08-01
Supplementary Document
2022-01-07
Supplementary Document
2022-08-01
Supplementary Document
2022-01-07
Supplementary Document
2022-01-07
Supplementary Document
2022-01-07
Supplementary Document
2022-01-07
Supplementary Document
2022-08-01
Supplementary Document
2022-01-07
Supplementary Document
2022-01-07
Supplementary Document
2022-01-07
ICR Details
202208-0923-001
Received in OIRA 202112-0923-001
HHS/TSDR 0923-22BJ
Evaluating the Association between Serum Concentrations of Per- and Polyfluoroalkyl Substances (PFAS) and Symptoms and Diagnoses of Selected Acute Viral Illnesses
New collection (Request for a new OMB Control Number)   No
Regular 08/02/2022
  Requested Previously Approved
36 Months From Approved
9,510 0
9,908 0
0 0

This study will assess the association between serum-PFAS levels and self-reported frequency of various groups of symptoms of viral infection (as a marker for susceptibility to viral infections). ATSDR will collect information through 5 surveys administered quarterly over the course of a year. Participants (anticipated n=4,075) will be asked about symptoms prospectively, as well as COVID information prospectively and retrospectively. Survey data will be linked to serum-PFAS levels that have been previously collected for ATSDR PFAS cohorts via survival analysis.

US Code: 42 USC 241 Name of Law: PHSA
  
None

Not associated with rulemaking

  86 FR 17600 04/05/2021
87 FR 974 01/07/2022
No

  Total Request Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 9,510 0 0 9,510 0 0
Annual Time Burden (Hours) 9,908 0 0 9,908 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
This is a New collection.

$322,000
Yes Part B of Supporting Statement
    Yes
    No
No
No
No
No
Kevin Joyce 404 639-1944 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
08/02/2022


© 2022 OMB.report | Privacy Policy